WhiteOak Capital Special Opportunities Fund
The Scheme seeks to generate long-term capital appreciation by investing in opportunities presented by special situations such as corporate restructuring (including mergers & acquisitions etc.), government policy and/or regulatory changes, technology led disruption and innovation, new trends, new & emerging sectors, companies/sectors going through temporary unique challenges and other similar instances.
Growthvine rating: 3/5 — ranked #56 of 186 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹14.79 (as of 2026-11-13) |
|---|
| AUM | ₹2,142 Cr |
|---|
| Expense ratio | 1.76% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dheeresh Pathak |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −17.26% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 142.3% of Nifty 500's upside and 92.3% of its downside.
Market cap allocation
| Large cap | 52.7% |
|---|
| Mid cap | 14.6% |
|---|
| Small cap | 32.7% |
|---|
Concentration
| Top 5 holdings | 22.6% |
|---|
| Top 10 holdings | 33.3% |
|---|
| Total holdings | 80 |
|---|
Top holdings
- ICICI Bank Ltd. — 7.0%
- Clearing Corporation of India Ltd — 6.7%
- Bharti Airtel Ltd. — 6.1%
- State Bank Of India — 3.5%
- Kotak Mahindra Bank Ltd. — 3.4%
- Reliance Industries Ltd — 2.6%
- Net Receivables / (Payables) — 2.6%
- Tech Mahindra Limited — 2.3%
- Divis Laboratories Ltd. — 2.3%
- Titan Company Limited — 2.1%
Top sectors
- Banking & Financial — 21.8%
- Cash — 9.3%
- Pharma & Biotech — 8.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 12.1% | Q1 (Top) | #31 of 167 |
| 2025 | 6.0% | Q2 | #49 of 132 |